On January 22, 2024 Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD), reported that it has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist (Press release, Quest Diagnostics, JAN 22, 2024, View Source,-developer-of-Haystack-MRD-TM-,-and-TriSalus-Life-Sciences-collaborate-in-connection-with-the-clinical-development-of-TriSalus-TLR9-agonist-in-hepatocellular-carcinoma,-intrahepatic-cholangiocarcinoma,-and-pancreatic-adenocarc [SID1234639410]). SD-101 is delivered via hepatic arterial infusion or pancreatic retrograde venous infusion in their phase 1 and 1b clinical trials using their proprietary Pressure-Enabled Drug Delivery (PEDD) to overcome the challenges associated with intratumoral pressure for patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Haystack MRD is specifically designed and developed to accurately detect circulating tumor DNA (ctDNA) with unparalleled sensitivity in patients with low tumor burden and in clinically challenging cancer types," said Dan Edelstein, Vice President and General Manager, Haystack Oncology. "Haystack MRD’s sensitivity enables clinical investigators to closely follow molecular response and measure early evidence of treatment efficacy. We’re excited to collaborate with TriSalus to support the clinical development of SD-101 in combination with their unique therapy delivery technology, which aims to overcome challenges associated with treating liver and pancreatic tumors."
Hepatocellular carcinoma is the most common form of liver cancer. Intrahepatic cholangiocarcinoma is cancer that occurs in the parts of the bile ducts that are within the liver. Pancreatic adenocarcinoma is the most common form of pancreatic cancer.
"A significant challenge in the development of immunotherapies for liver and pancreatic tumors is early measurement of response to treatment. Conventional imaging response assessment methods may be misleading in certain situations, and accurate ctDNA assays offer the potential to identify meaningful biologic activity in difficult to treat cancers," says Steven Katz, MD, Chief Medical Officer of TriSalus Life Sciences. "We are thrilled to work with Haystack in pursuit of our mission to develop better therapeutic options for patients with liver and pancreatic tumors."